Eicosanoids in Cancer: Prostaglandin E2 Receptor 4 in Cancer Therapeutics and Immunotherapy

The cyclooxygenase-2 (COX-2) enzyme is frequently overexpressed in epithelial malignancies including those of the breast, prostate, lung, kidney, ovary, and liver and elevated expression is associated with worse outcomes. COX-2 catalyzes the metabolism of arachidonic acid to prostaglandins. The COX-2 product prostaglandin E2 (PGE2) binds to four G-protein-coupled EP receptors designated EP1–EP4. EP4 is commonly upregulated in cancer and supports cell proliferation, migration, invasion, and metastasis through activation of multiple signaling pathways including ERK, cAMP/PKA, PI3K/AKT, and NF-κB. EP4 antagonists inhibit metastasis in preclinical models. Cancer stem cells, that underlie therapy resistance and disease relapse, are driven by the expression of EP4. Resistance to several chemotherapies is reversed in the presence of EP4 antagonists. In addition to tumor cell-autonomous roles of EP4, many EP4-positive host cells play a role in tumor behavior. Endothelial cell-EP4 supports tumor angiogenesis and lymphangiogenesis. Natural Killer (NK) cells are critical to the mechanism by which systemically administered EP4 antagonists inhibit metastasis. PGE2 acts on EP4 expressed on the NK cell to inhibit tumor target cell killing, cytokine production, and chemotactic activity. Myeloid-derived suppressor cells (MDSCs), that inhibit the development of cytotoxic T cells, are induced by PGE2 acting on myeloid-expressed EP2 and EP4 receptors. Inhibition of MDSC-EP4 leads to maturation of effector T cells and suppresses the induction of T regulatory cells. A number of EP4 antagonists have proven useful in dissecting these mechanisms. There is growing evidence that EP4 antagonism, particularly in combination with either chemotherapy, endocrine therapy, or immune-based therapies, should be investigated further as a promising novel approach to cancer therapy. Several EP4 antagonists have now progressed to early phase clinical trials and we eagerly await the results of those studies.

[1]  S. Koizumi,et al.  Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action , 2020, Frontiers in Immunology.

[2]  Y. Sakai,et al.  Prostaglandin E2/EP Signaling in the Tumor Microenvironment of Colorectal Cancer , 2019, International journal of molecular sciences.

[3]  R. Islam,et al.  Prostaglandin E2 receptor EP4 regulates cell migration through Orai1 , 2019, Cancer science.

[4]  Qi-hao Zhang,et al.  Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer. , 2019, The international journal of biochemistry & cell biology.

[5]  M. Neunlist,et al.  Tumor cells hijack enteric glia to activate colon cancer stem cells and stimulate tumorigenesis , 2019, EBioMedicine.

[6]  Gautam G. Rao,et al.  EP4 and Class III β-Tubulin Expression in Uterine Smooth Muscle Tumors: Implications for Prognosis and Treatment , 2019, Cancers.

[7]  K. Tsuneyama,et al.  Inhibition of EP2/EP4 prostanoid receptor-mediated signaling suppresses IGF-1-induced proliferation of pancreatic cancer BxPC-3 cells via upregulating γ-glutamyl cyclotransferase expression. , 2019, Biochemical and biophysical research communications.

[8]  J. Ryu,et al.  Inflammatory mediators of prostate epithelial cells stimulated with Trichomonas vaginalis promote proliferative and invasive properties of prostate cancer cells , 2019, The Prostate.

[9]  Xiaolei Shi,et al.  The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming , 2019, Journal of experimental & clinical cancer research : CR.

[10]  L. Ellis,et al.  Inhibition of PGE2/EP4 receptor signaling enhances oxaliplatin efficacy in resistant colon cancer cells through modulation of oxidative stress , 2019, Scientific Reports.

[11]  R. Tate,et al.  The prostaglandin EP4 receptor is a master regulator of the expression of PGE2 receptors following inflammatory activation in human monocytic cells. , 2018, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[12]  Yung-Hyun Choi,et al.  Cordycepin inhibits lipopolysaccharide-induced cell migration and invasion in human colorectal carcinoma HCT-116 cells through down-regulation of prostaglandin E2 receptor EP4 , 2018, BMB Reports.

[13]  H. Herschman,et al.  PGE2/EP4 antagonism enhances tumor chemosensitivity by inducing extracellular vesicle‐mediated clearance of cancer stem cells , 2018, International journal of cancer.

[14]  Haiyoung Jung,et al.  Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation , 2018, Front. Immunol..

[15]  A. Omar,et al.  EP4 as a Therapeutic Target for Aggressive Human Breast Cancer , 2018, International journal of molecular sciences.

[16]  Zhengyu Zhang,et al.  Prostaglandin E2 receptor EP4 is involved in the cell growth and invasion of prostate cancer via the cAMP‑PKA/PI3K‑Akt signaling pathway. , 2018, Molecular medicine reports.

[17]  E. Sahai,et al.  NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control , 2018, Cell.

[18]  S. Inoue,et al.  Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression , 2017, British Journal of Cancer.

[19]  A. Mortazavi,et al.  Prostaglandin E2 Leads to the Acquisition of DNMT3A-Dependent Tolerogenic Functions in Human Myeloid-Derived Suppressor Cells. , 2017, Cell reports.

[20]  G. Kuznetsov,et al.  EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity , 2017, Oncoimmunology.

[21]  Y. Daaka,et al.  Prostaglandin E2 receptor 4 mediates renal cell carcinoma intravasation and metastasis. , 2017, Cancer letters.

[22]  A. Cambi,et al.  EP4 receptor promotes invadopodia and invasion in human breast cancer. , 2017, European journal of cell biology.

[23]  P. Nandi,et al.  PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells , 2017, BMC Cancer.

[24]  H. Marriott,et al.  The anti‐inflammatory effects of PGE2 on human lung macrophages are mediated by the EP4 receptor , 2016, British journal of pharmacology.

[25]  Kenta Watanabe,et al.  Abrogation of prostaglandin E-EP4 signaling in osteoblasts prevents the bone destruction induced by human prostate cancer metastases. , 2016, Biochemical and biophysical research communications.

[26]  Nathan D. VanderKraats,et al.  Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer , 2016, Oncogene.

[27]  Chun-hui Yuan,et al.  Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2 , 2016, Scientific Reports.

[28]  S. Akira,et al.  Direct Melanoma Cell Contact Induces Stromal Cell Autocrine Prostaglandin E2-EP4 Receptor Signaling That Drives Tumor Growth, Angiogenesis, and Metastasis* , 2015, The Journal of Biological Chemistry.

[29]  J. Kappes,et al.  Therapeutic intervention of proanthocyanidins on the migration capacity of melanoma cells is mediated through PGE2 receptors and β-catenin signaling molecules. , 2015, American journal of cancer research.

[30]  A. Dent,et al.  MicroRNA 21 Is a Homeostatic Regulator of Macrophage Polarization and Prevents Prostaglandin E2-Mediated M2 Generation , 2015, PloS one.

[31]  K. Izumi,et al.  Inhibition of EP2/EP4 signaling abrogates IGF-1R-mediated cancer cell growth: Involvement of protein kinase C-θ activation , 2014, Oncotarget.

[32]  J. Rundhaug,et al.  The tumor promoting activity of the EP4 receptor for prostaglandin E2 in murine skin , 2014, Molecular oncology.

[33]  P. Lala,et al.  Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions , 2014, Cancer science.

[34]  B. Seliger,et al.  Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity , 2014, Clinical Cancer Research.

[35]  Paul N. Staats,et al.  Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties , 2013, Breast Cancer Research and Treatment.

[36]  R. A. Evans,et al.  Mammary Carcinoma Cell Derived Cyclooxygenase 2 Suppresses Tumor Immune Surveillance by Enhancing Intratumoral Immune Checkpoint Activity , 2013, Breast Cancer Research.

[37]  Xinrong Ma,et al.  A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis , 2013, Oncoimmunology.

[38]  P. Collin,et al.  Modulation of Host Natural Killer Cell Functions in Breast Cancer via Prostaglandin E2 Receptors EP2 and EP4 , 2012, Journal of immunotherapy.

[39]  A. Fulton,et al.  Prostaglandin E2 EP receptors as therapeutic targets in breast cancer , 2011, Cancer and Metastasis Reviews.

[40]  C. Jean,et al.  PGE2 inhibits natural killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling. , 2010, Biochemical pharmacology.

[41]  Y. Daaka,et al.  Prostaglandin E2 Promotes Lung Cancer Cell Migration via EP4-βArrestin1-c-Src Signalsome , 2010, Molecular Cancer Research.

[42]  Yasushi Okuno,et al.  Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. , 2010, Cancer research.

[43]  S. Ostrand-Rosenberg,et al.  Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function , 2009, Breast Cancer Research and Treatment.

[44]  M. Hull,et al.  Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells , 2007, Oncogene.

[45]  P. Sinha,et al.  Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. , 2007, Cancer research.

[46]  T. Maruyama,et al.  Prostaglandin E receptor EP4 antagonist suppresses osteolysis due to bone metastasis of mouse malignant melanoma cells , 2007, FEBS letters.

[47]  D. Carbone,et al.  Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. , 2006, Cancer research.

[48]  Xinrong Ma,et al.  Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. , 2006, Cancer research.

[49]  Y. Kadowaki,et al.  Activation of prostaglandin E2-receptor EP2 and EP4 pathways induces growth inhibition in human gastric carcinoma cell lines. , 2002, The Journal of laboratory and clinical medicine.

[50]  Y. Song,et al.  Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells. , 2009, Carcinogenesis.